Macrophage migration inhibitory factor (MIF) is a pivotal regulator of the immune response. Neutralization or genetic deletion of MIF does not completely abrogate activation responses, however, and deletion of the MIF receptor, CD74, produces a more pronounced phenotype than MIF deficiency. We hypothesized that these observations may be explained by a second MIF-like ligand, and we considered a probable candidate to be the protein encoded by the homologous, D-dopachrome tautomerase (D-DT) gene. We show that recombinant D-DT protein binds CD74 with high affinity, leading to activation of ERK1/2 MAP kinase and downstream proinflammatory pathways. Circulating D-DT levels correlate with disease severity in sepsis or malignancy, and the specific immunoneutralization of D-DT protects mice from lethal endotoxemia by reducing the expression of downstream effector cytokines. These data indicate that D-DT is a MIF-like cytokine with an overlapping spectrum of activities that are important for our understanding of MIF-dependent physiology and pathology.
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inflammation | lipopolysaccharide | septic shock M acrophage migration inhibitory factor (MIF) is the first cytokine activity described and a key regulatory mediator that is released upon activation of different cell types (1) (2) (3) . MIF increases macrophage antimicrobial responses and it is expressed upstream of cytokines such as tumor necrosis factor (TNF)-α, IFN-γ, and IL-1β (4) . MIF activates immune cells by binding to CD74, leading to the recruitment of CD44 into a signaling complex, the stimulation of nonreceptor tyrosine kinases, and initiation of the ERK1/2 MAP kinase pathway (5, 6) . The chemokine receptors CXCR2 and CXCR4 also become activated by MIF via noncognate interactions that are reinforced in the presence of CD74 (7) . Among mesenchymal cell types, MIF binding to cardiomyocyte CD74 stimulates the AMP-activated kinase (AMPK) cascade to mediate protection from ischemic injury (8, 9) .
Although MIF receptor knockout mice (CD74
) phenocopy features of MIF deficiency (10) (11) (12) , recent observations have led to the hypothesis that there may be a second ligand for CD74. MIF-deficient B cells, for example, are more sensitive to apoptosis than wild-type B cells, but the magnitude of this defect is twofold more pronounced in CD74-deficient cells (13) . Intravital microscopy studies also have shown a more pronounced effect of antagonism of CD74 than MIF in monocyte arrest (7) . Finally, anti-MIF antibodies, although highly effective in experimental studies, do not completely inhibit CD74-dependent cellular activation responses (14) .
We hypothesized that these observations may be explained by a second MIF-like ligand, and we considered a likely candidate to be the protein encoded by the DDT gene, D-dopachrome tautomerase (D-DT). DDT and MIF show a conserved intron-exon structure and their coding regions are highly homologous. The genes for MIF and D-DT are in close apposition to each other and to two theta-class glutathione S-transferases, suggesting that these gene clusters arose by an ancestral duplication event (Fig. 1) .
D-DT was named for its ability to tautomerize the nonnaturally occurring, D-stereoisomer of dopachrome, which is a catalytic property shared with MIF. This activity has been hypothesized to be a vestigial function that reflects MIF's ancestral origin in the invertebrate melanotic encapsulation response (15) . A crystal structure of D-DT has verified its 3D similarity with MIF (16) . With the exception of recent studies indicating an interaction between the MIF and DDT genes in the expression of proangiogenic factors and COX-2 in adenocarcinoma cell lines (17, 18) , there have been no studies of the biologic functions of D-DT. In this report, we describe the functional characterization of human and mouse D-DT. We produced recombinant D-DT and demonstrate that it binds with high affinity to CD74, activates the ERK1/2 MAP kinase signaling cascade, and recapitulates many of the inflammatory functions of MIF, including modulation of macrophage migration and glucocorticoidinduced immunosuppression. The administration of an anti-DDT antibody, like anti-MIF, protects mice from lethal endotoxic shock by reducing the circulating levels of proinflammatory cytokines (TNF-α, IFN-γ, IL-12p70, and IL-1β) and increasing the circulating concentration of the anti-inflammatory cytokine, IL-10. An analysis of clinical samples from patients with sepsis or cancer also revealed that D-DT is systemically expressed and that circulating levels correlate with MIF and with the severity of inflammatory disease and malignancy.
Results
Purification and Characterization of the D-DT Protein. The genes for MIF and D-DT lie within 0.1 kb of each other in both the mouse and human genomes and have a similar organizational relationship with nearby genes for matrix metalloproteinase 11 and two theta class GSTs (Fig. 1) . The amino acid sequences show 34% identity between human MIF and human D-DT and 27% identity between murine MIF and murine D-DT. The D-DT proteins share with MIF a canonical N-terminal proline (formed after posttranslational excision of the initiating methionine), which catalyzes substrate tautomerization (19) , but they lack two of the three conserved cysteines (Cys 59 and Cys 80 ) that appear in all known mammalian MIF proteins. Murine and human D-DT also lack the pseudo(E)LR (Arg 11 , Asp 44 ) motif that mediates MIF's noncanonical interactions with the CXCR2 chemokine receptor (20) . The mRNA for D-DT does not encode either an N-terminal or an internal secretory signal sequence, suggesting that like MIF, D-DT is secreted by a specialized, nonclassical export pathway (21) .
The cDNAs for human and mouse D-DT were prepared from monocytes and cloned into a bacterial expression vector for recombinant protein production. We considered it critical to work with native sequence proteins because of structure-function studies that have shown that modifications of the N or C termini interfere with trimer formation, the functional unit of MIF (19, 22, 23) . Recombinant D-DT protein was purified by anion exchange chromatography followed by high performance liquid chromatography (HPLC) (Fig. 2A) . Mass spectroscopy of purified mouse D-DT protein gave an m/z of 12,947, which lies within 0.02% of the calculated mass for D-DT (Fig. 2B) . A minor peak of 13,079 Da also was detected; this peak corresponds to the molecular mass of D-DT with an uncleaved N-terminal methionine (expected m/z = 13,077).
MIF tautomerizes model substrates such as D-dopachrome and p-hydoxyphenylpyruvate (HPP) (whether a physiological substrate exists is unknown) (15) , and D-DT purified from liver has tautomerization activity (24, 25) . We verified that recombinant D-DT tautomerizes HPP with a specific activity that is ∼10 times lower than that measured for MIF (D-DT = 0.5 ± 0.1 Δ306·min −1 ·μM −1 , and MIF = 4.3 ± 1.1 Δ306·min
, P < 0.001) (Fig. 2C) . A possible explanation for the discrepancy in activity might be structural differences in the active site regions of D-DT and MIF, resulting in a reduced affinity of D-DT to its substrate (16, 22) . A polyclonal anti-DDT antibody was prepared to establish an ELISA. This antibody recognized both murine and human D-DT but did not cross-react with MIF in its denatured form (assessed by Western blot; Fig. 2D , Left) or in its native form (assessed by ELISA; Fig. 2D , Right).
D-DT Binds the MIF Receptor, CD74, and the Intracellular Protein, JAB1. MIF activates ERK1/2 phosphorylation by engaging CD74, and a high-affinity binding interaction between MIF and the CD74 ectodomain (CD74 73-232 or sCD74) has been demonstrated by surface plasmon resonance (6) . We first studied the interaction between D-DT and sCD74 in a competition binding assay. D-DT reduced MIF binding to the CD74 ectodomain in a dose-dependent manner, with a maximal effect of ∼50% compared with MIF (Fig. 3A) . , respectively). These measurements demonstrate that D-DT has an ∼3-fold higher binding rate to the receptor CD74, but also dissociates much faster than MIF.
The intracellular transcriptional regulator and COP9 signalosome component JAB1 is a well characterized binding partner of MIF that has been implicated in MIF-dependent control of cell proliferation (26) . D-DT binds to JAB1 as demonstrated by coimmunoprecipation (Fig. 3C) , and the interaction affinity between JAB1 and D-DT appears comparable to that observed between JAB1 and MIF.
Differential Expression of D-DT and MIF. We assessed the possibility that D-DT may be differentially expressed in tissue compared with MIF. Esumi et al. have published Northern blotting data for Ddt expression that suggest enhanced expression in the murine brain compared with Mif (27). We analyzed eight different mouse organs by Western blotting for D-DT, MIF, and CD74. D-DT and MIF were present in constitutive and appreciable levels in all tissues examined, with the greatest difference observed in the testis, where D-DT appeared in severalfold higher concentrations compared with MIF ( Fig. 3D) . Immunostaining of murine tissue confirmed these results and showed that D-DT, like MIF (28) , is detected in virtually all cells, with prominent staining in the epithelia of the kidney, the lung, the bowel, hepatocytes, and the follicular area of the spleen (Fig. 3E ).
D-DT Initiates ERK-1/2 Phosphorylation in a MIF Receptor-ComplexDependent Manner, Mediates Macrophage Migration Arrest, and
Counterregulates Glucocorticoid-Induced Immunosuppression. MIF binding to CD74 leads to the recruitment of CD44 and the intracellular phosphorylation of these proteins, resulting in the activation of SRC family nonreceptor tyrosine kinases and the initiation of the ERK1/2 MAP kinase cascade (5, 6) . Stimulation of cultured macrophages with increasing concentrations of recombinant D-DT produced a dose-dependent phosphorylation of ERK1/2, with an activating effect that was both sustained (2 h) (29) and comparable to that observed for MIF (Fig. 4A , Top). Costimulation with D-DT and MIF revealed an additive effect of the two proteins in the ERK1/2 MAP kinase pathway (Fig. 4A , Middle). D-DT-induced ERK1/2 phosphorylation was strictly dependent on the expression of both CD74 and CD44, as previously reported for MIF (5) (Fig. 4A, Bottom) .
We analyzed the biologic activity of recombinant D-DT by first assaying for MIF's effect on macrophage chemotaxis (30) . D-DT inhibited chemotaxis induced by CCL2/monocyte chemotactic protein (MCP)-1, but with a less steep dose response and re- duced inhibitory action at 1 μg/mL compared with MIF (Fig. 4B) . This observation may be explained by the reduced binding affinity of D-DT for the MIF receptor or different rates of ligand association/dissociation and a consequent reduction in the downstream events necessary for CCL2 desensitization.
MIF is unique among immune mediators in its ability to counterregulate the immunosuppressive action of glucocorticoids, which occurs via intracellular pathways that involve cytoplasmic phospholipase A2, IκB1, and MKP-1 (31) (32) (33) . Using a standardized assay (31), we further observed that D-DT, like MIF, counterregulated the inhibitory effect of glucocorticoids on TNF production from lipopolysaccharide (LPS)-stimulated macrophages (Fig. 4C ). Similar to observations in the migration assay, D-DT shows a decreased counterregulatory potential at low concentrations compared with MIF, which may be attributed to lower binding affinity to the MIF receptor.
D-DT Is Produced in Response to LPS and Mediates Lethal Endotoxemia. Whereas macrophages have been considered historically to be a main target of MIF action, these cells also are a major source of MIF production in response to microbial products and tissue invasion in vivo (34) . Cultured macrophages were stimulated with 1 μg/mL of Escherichia coli LPS and the secretion of D-DT and MIF was quantified by specific ELISA. LPS-stimulated macrophages released D-DT into conditioned medium with kinetics that were very similar to those of MIF (Fig. 5A) . Peak levels were detectable at 16 h and decreased thereafter. Unstimulated cells also slowly released these proteins into supernatants, which in the case of MIF has been attributed to a low level of constitutive secretion (21) . We addressed whether there may be reciprocal regulation of D-DT and MIF expression in macrophages. We depleted D-DT or MIF in immortalized macrophages by siRNA-mediated knockdown but detected no effect on the expression level of the reciprocal protein in response to LPS stimulation (Fig. 5B) .
The administration of LPS to mice resulted in a timedependent increase in plasma D-DT concentrations (6.0 ± 4.3 ng/mL to 26 ± 12 ng/mL at 24 h), and this increase mimicked the rise observed for MIF (1.0 ± 0.9 ng/mL to 43 ± 28 ng/mL at 24 h) (Fig. 5C ). D-DT also is detectable in plasma under basal conditions and at comparable levels to MIF (D-DT = 6.0 ± 4.3 ng/ mL and MIF = 1.0 ± 0.9 ng/mL) (31). It is noteworthy that whereas plasma MIF and D-DT circulate in similar concentrations under basal or stimulated conditions, LPS-stimulated macrophages produce 20-fold more MIF than D-DT (Fig. 5A) . This observation suggests that nonmacrophage sources of D-DT contribute significantly to plasma D-DT expression in vivo.
Immunoneutralization of D-DT Protects from Lethal Endotoxemia.
Immunoneutralization or genetic deletion of MIF protects mice from endotoxic shock (35, 36) and subsequent studies demonstrated that this protective effect is due to a reduction in the expression of tissue-damaging, effector cytokines such as TNF and IL-1 (37, 38) . The administration of a specific anti-DDT antibody before the injection of an LD 80 dose of LPS increased survival from 20 to 79% (Fig. 5D) , which is a level of protection comparable to that of anti-MIF (35) . An analysis of plasma cytokine expression showed that D-DT neutralization was associated with a significant reduction in the circulating concentration of several proinflammatory cytokines (TNF-α, IL-1β, IFN-γ, and IL-12p70) implicated in shock pathogenesis (Fig. 5E ). In contrast, the concentration of the anti-inflammatory cytokine IL-10 was increased in the anti-DDT-treated group compared with controls.
D-DT Expression Is Up-Regulated in Patients with Sepsis or Invasive
Cancer. To determine whether D-DT is up-regulated in human disease and to assess potential relationships between D-DT and MIF production in vivo, we analyzed the serum concentrations of these mediators in individuals with sepsis or with ovarian cancer, which are two conditions characterized by high levels of MIF in plasma (38, 39) . There was a statistically significant increase in circulating D-DT protein in patients with sepsis compared with healthy controls (sepsis patients, 55.5 ± 61.3 ng/mL; control group, 5.9 ± 3.9 ng/mL; P < 0.0001) (Fig. 6A) . MIF levels also were elevated, as expected from prior work (38, 40, 41) (sepsis patients,111.0 ± 69.0 ng/mL; control group, 6.3 ± 6.2 ng/mL; P < 0.0001). Receiver operator characteristic (ROC) analysis revealed an area under the curve of 0.99 for MIF or D-DT, indicating that both proteins show excellent sensitivity and specificity for the diagnosis of sepsis. These measurements further revealed that serum levels of D-DT, like MIF (40, 42) , correlate with disease severity as determined by APACHE II clinical severity scores (Fig. 6B) . Both D-DT and MIF show a significant association with outcome parameters; however, a more precise assessment of the prognostic value of these proteins may be obtained by serial measurements. Serum D-DT and MIF concentrations also correlate in healthy individuals, and the correlation coefficient increases from R = 0.32 to R = 0.5 for the analysis of these mediators in patients with sepsis (Fig. 6C) .
We also found circulating D-DT concentrations to be elevated in patients with ovarian cancer (cancer patients, 15.2 ± 13.8 ng/ mL; control group, 5.9 ± 3.9 ng/mL; P < 0.0001) (Fig. 6D) . ROC analysis revealed an area under the curve of 0.8, which is comparable to that observed for MIF (0.7). The correlation between MIF and D-DT serum concentrations was stronger and showed greater statistical significance than that observed for septic patients (R = 0.9, P = 0.0001).
Discussion
We report herein the functional characterization of the eukaryotic MIF homolog, D-DT. MIF and D-DT are highly conserved in their overall genomic structure, amino acid sequence similarity, and MIF receptor activation properties. Both mouse and human D-DT proteins show conservation in their catalytic, N-terminal proline but they lack MIF's −CXXC-and pseudo(E)LR motifs, the latter of which mediates noncognate interactions with CXCR2 and CXCR4 (7, 20) . We produced recombinant, endotoxin-free D-DT protein and demonstrated that D-DT, like MIF, tautomerizes the model substrate, p-hydroxyphenylpyruvate, albeit the measured velocity is ∼10 times lower than that analyzed for MIF. D-DT is constitutively expressed in different tissues and it is up-regulated by proinflammatory activation.
MIF binds to the type II transmembrane protein, CD74, leading to its intracellular phosphorylation, the recruitment of the coreceptor CD44, and the activation of SRC family kinases and the ERK1/2 MAPK pathway (5, 6) . Although the interaction between D-DT and sCD74 was reduced in comparison with MIF when measured by both competition binding and BIAcore studies, the ERK1/2 activation potential of D-DT and MIF appeared comparable by Western blotting. The K D of sCD74 for D-DT was 60% of that measured for MIF; D-DT was found to have an ∼3-fold higher association rate (k a ) to sCD74 but to dissociate (k d ) ∼11-fold faster than MIF. These differences in association and dissociation values may differentiate the signaling action of the two proteins; e.g., D-DT binding to the receptor might not always trigger a signaling cascade but might result in its internalization. MIF showed a steeper dose response than D-DT in measurements of macrophage migration inhibition and glucocorticoid overriding, but the resolution of these cell-based assays may be too limited to make precise, quantitative conclusions. These results may support the notion that D-DT is a less potent cytokine that might be associated with the down-regulation of inflammation.
We produced anti-DDT antibodies that do not cross-react with MIF; these antibodies allowed for measurements of this protein in biologic specimens. D-DT was expressed in the serum of endotoxemic mice at levels that were ∼60% those of MIF. MIF is a high, upstream mediator of septic shock, and immunoneutralization, genetic deletion, or pharmacologic inhibition of MIF protects from lethal shock induced by different microbial pathogens, even when administered many hours after microbial invasion (35, 36, (43) (44) (45) . Immunoneutralization of D-DT conferred protection from lethal endotoxemia and this effect was accompanied by a broad reduction in the systemic expression of TNF-α, IL-1β, IL-12p70, and IFN-γ and an increase in the circulating levels of the anti-inflammatory mediator, IL-10. Given current development of MIF inhibitors for the treatment of the inflammatory diseases (44, 46, 47) , it would be of interest to determine whether the combined neutralization of MIF and D-DT has a synergistic effect.
MIF levels are elevated in patients with systemic inflammatory disease or with neoplasia, and in many instances a correlation between disease severity and MIF levels has been observed (48) . Like MIF, D-DT circulates at baseline levels in healthy individuals and there is a correlation in the plasma concentrations of the two mediators. Circulating D-DT levels increase significantly in patients with sepsis or ovarian cancer and show a strong correlation with MIF, suggesting that the two mediators may be coordinately expressed in response to similar activating stimuli.
Our main findings that D-DT is a close structural and functional homolog of MIF, that it binds and activates the MIF receptor, and that targeting D-DT, similar to MIF, protects mice from lethal endotoxemia raise the question: What are the distinctive functional features of D-DT, if any, compared with MIF? Like MIF (28), D-DT is widely expressed in tissues. We did find that macrophages produce 20-fold more MIF than D-DT in response to LPS, suggesting that there may be cell-specific release of these mediators and that in contrast to MIF, nonmacrophage sources of D-DT contribute more importantly to the systemic expression of D-DT than MIF. Computational inspection of the D-DT and MIF promoter regions shows similarities in the presence of serum-responsive, SP-1 and AP-1 binding elements (http://alggen.lsi.upc.es/). Of note, the human DDT gene lacks the polymorphic, CATT 5-8 microsatellite repeat that exists in the MIF promoter (rs5844572) and that regulates MIF expression and is associated with the severity of autoimmune inflammatory diseases (48) . Conceivably, one difference between MIF and DDT may lie in the allele-specific regulation of MIF expression but not D-DT, although this conclusion will require closer investigation of potential DDT polymorphisms.
At the protein level, D-DT lacks MIF's pseudo(E)LR domain, which is necessary for activation of CXCR2. Bernhagen and colleagues have reported that MIF initiates coordinated receptor interactions between CD74 and CXCR2/CXCR4 (7, 20) . D-DT's high binding affinity to CD74 also may facilitate direct chemotactic effects, perhaps in concert with MIF or IL-8, which is expressed upon CD74 signaling (18, 49) . D-DT binds the intracellular protein, JAB1, indicating that it might affect the regulation of cell cycle control and signalosome function, similarly to MIF (26) . Like MIF, D-DT lacks an N-terminal signal sequence and it may be produced in sufficient intracytoplasmic concentrations to influence these regulatory pathways.
In conclusion, these data identify D-DT to be a cytokine and a close functional homolog of MIF. We propose that D-DT be designated "MIF-2", which would be in accordance with the nomenclature for nematode MIF-like genes (50) and a prior suggestion that the DDT gene product be renamed to more appropriately reflect its function (51) . Better definition of D-DT (MIF-2) versus MIF (MIF-1) functions may be uncovered by the development of a Ddt-KO mouse, which is underway. Finally, we note that the current emphasis on the development MIFdirected therapies, which have shown strong efficacy in different preclinical models of disease, may be enhanced by the simultaneous targeting of D-DT.
Materials and Methods
Cloning and Purification of D-DT Protein. The cDNAs for the human and mouse D-DT proteins were prepared by amplification of mRNA from human or murine monocytes and subcloned into the pET22b expression vector. For native protein expression, a stop codon was engineered. Bacterial extract was purified using a Q Sepharose column (Amersham) and subsequent HPLC using a C18 column (Amersham). D-DT was refolded using the protocol established for MIF renaturation (52) . Protein purity was verified by Coomassie and fidelity confirmed by mass spectroscopy. The resulting proteins contained <1 pg LPS/μg protein as quantified by the PyroGene Recombinant Factor C assay (Cambrex). MIF proteins were produced as described earlier (52) . D-dopachrome tautomerase activity was assessed using the substrate HPP, measuring the change in absorbance at 306 nm for 180 s (53).
Anti-DDT Antibody and ELISA. Polyclonal antibodies against recombinant mouse or human D-DT were produced in rabbits. IgG antibody fractions were isolated by Protein A agarose affinity chromatography (Pierce) and sterile filtered. Microtiter plates (Nunc) were coated with 15 μg/mL of polyclonal anti-DDT, washed, and blocked in 1% BSA and 1% sucrose. Samples were added and incubated for 2 h, followed by biotinylated anti-DDT antibody and a streptavidin-HRP conjugate. The D-DT concentrations were calculated by extrapolation from a sigmoidal quadratic standard curve using native D-DT protein (dynamic range, 0-625 pg/mL). For mouse or human D-DT, the detection limit was 15 pg/mL. MIF Receptor Binding Studies. Binding of D-DT to the MIF receptor, CD74, was studied by competition binding assay as described previously (6) . Real-time binding interaction of MIF or D-DT with CD74
73-232 was measured by surface plasmon resonance using a BIAcore 2000 optical biosensor (54) . The MIF receptor sCD74 was immobilized to the chip, and binding of the ligands D-DT and MIF was measured in five serial dilutions, three times for each dilution sample. Sensorgram response data were analyzed in the BIA evaluation kinetics package and the equilibrium binding constants calculated in the same experiment. D-DT Protein Expression in Murine Tissues. Tissues were isolated from C57BL/6 mice, and proteins were analyzed by Western blot (28) . For immunohistochemistry, tissue sections from C57BL/6 mice (10) were deparaffinized and antigen retrieval was performed using the Target Retrieval Solution (Dako). The specificity of anti-DDT antibody staining was established by preabsorbing an aliquot of the antibody with a 1,000-fold molar excess of either D-DT or MIF. Slides were incubated with rabbit anti-DDT or IgG control antibody (1:50) overnight and visualized with the Liquid DAB + Substrate Chromogen System (Dako). To allow a semiquantitative comparison of different tissues, all slides were developed for 10 min.
siRNA-Mediated Knockdown of D-DT and MIF. Immortalized murine macrophages (55) were transfected with 50 nM siRNA using HiPerFect (Qiagen). Sequences used were 5′-TCAACTATTACGACATGAA-3′ for MIF and 5′-GCA-TGACCCTGTTGATGAA-3′ for D-DT.
Signal Transduction Studies. Mouse peritoneal macrophages (1 × 10 6 /well) were rendered quiescent by incubation in 0.1% FBS before stimulation with D-DT or MIF for 2 h (29). Cells were lysed in RIPA buffer and lysates were run on a 4-12% Bis-Tris NuPage gel (Invitrogen). Immunoblotting was conducted with Abs directed against total ERK1/2, and phospho-ERK-1/2 (Cell Signaling).
Migration and Glucocorticoid Overriding Assays. Migration assays were performed as described previously (30) . Briefly, human monocytes were incubated for 20 min with MIF or D-DT. Media with or without 25 ng/mL MCP-1 was added in the lower compartment of migration chambers and monocytes was added to the transwell (0.5-μm pore size) for 90 min. Cells from the lower migration chamber were lysed, and DNA was fluorescently labeled and enumerated at 480/520 nm. Following the original glucocorticoid overriding methodology of Calandra et al. (31) , macrophages were preincubated for 1 h with 100 nM dexamethasone (Sigma) and MIF or D-DT before adding 100 ng/mL LPS (Sigma). TNF levels in supernatants were measured by ELISA (eBioscience).
MIF/JAB1 Coimmunoprecipitation. Mif −/− MEFs were lysed in ice-cold buffer and incubated with MIF or D-DT, respectively (26) . Two micrograms of anti-JAB1 (2A10.8; Gene Tex/Biozol) or IgG1 control was added and the protein complexes were pulled down with magnetic protein G beads (Invitrogen). Blotted proteins were visualized using an anti-MIF or anti-DDT antibodies and then reprobed with anti-JAB1 antibody.
Endotoxemia Model. Endotoxemia was induced in female BALB/c mice (8 wk old) by i.p. administration of E. coli LPS 0111:B4 (Sigma) at a dose of 12.5 mg/ kg for serum cytokine measurement and 20 mg/kg for intervention experiments (LD 80 ). For D-DT neutralization studies, mice were injected i.p. with 200 μL of rabbit anti-D-DT antiserum or nonimmune serum 2 h before administration of LPS. Mice were monitored every 4 h within the first 72 h and then twice daily until death or until 14 d. Cytokine levels were obtained by bleeding mice 4, 24, and 36 h after LPS challenge, and serum cytokines were analyzed by Luminex (Bio-Rad).
Patient Samples. Serum concentrations of D-DT and MIF were measured in 85 healthy individuals and in 37 septic patients hospitalized in the medical intensive care unit (56) . The median APACHE II score at the time of intensive care unit admission was 22 points (range: 10−36 points). The mortality rate was 27%. The etiologic agents of sepsis were Gram-negative bacteria (43%) and Gram-positive bacteria (49%). Two patients had an infection with Grampositive and Gram-negative bacteria and one with fungi. Sera from women with biopsy-proven ovarian cancer (n = 21) were from Yale-New Haven Hospital.
